- Previous Close
0.00 - Open
20.23 - Bid 15.95 x 36900
- Ask 18.65 x 38500
- Day's Range
20.23 - 20.85 - 52 Week Range
18.06 - 20.85 - Volume
1,100 - Avg. Volume
6 - Market Cap (intraday)
1.459B - Beta (5Y Monthly) 0.26
- PE Ratio (TTM)
18.21 - EPS (TTM)
1.10 - Earnings Date Feb 20, 2025
- Forward Dividend & Yield 0.32 (1.62%)
- Ex-Dividend Date May 21, 2024
- 1y Target Est
--
Fagron NV, a pharmaceutical compounding company, delivers personalized pharmaceutical care to hospitals, pharmacies, clinics, and patients worldwide. It operates in three segments: Essentials, Brands, and Compounding Services. The company also innovates concepts, vehicles, and formulations for pharmaceutical compounding. Its products include DiluCap, a line of excipients to compound every capsule formulation; Imuno TF Complex helps in regulation of immune responses; Pigmerise, a natural phytocomplex for hypopigmentation disorders; Pentravan uses for avoiding first-pass metabolism and preventing gastrointestinal erosion; Nourisil MD, a first line therapy for prevention and treatment of scars ang keloids; Neogen, a line of hair care products; TrichoConcept used to treat alopecia; Fagron Advanced Derma for basic skincare, compound pharmaceutical treatment, and individualized dermatological care; and SyrSpend SF that provides pharmaceutical stability, dosage consistency, and patient comfort. In addition, the company offers education and training program to prescribers and pharmacists through the Fagron Academy. The company was formerly known as Arseus NV and changed its name to Fagron NV in January 2015. Fagron NV was founded in 1990 and is based in Nazareth, Belgium.
www.fagron.com3,647
Full Time Employees
December 31
Fiscal Year Ends
Sector
Recent News: ARSUF
View MorePerformance Overview: ARSUF
Trailing total returns as of 1/15/2025, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: ARSUF
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: ARSUF
View MoreValuation Measures
Market Cap
1.25B
Enterprise Value
1.53B
Trailing P/E
18.24
Forward P/E
15.75
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
1.74
Price/Book (mrq)
3.00
Enterprise Value/Revenue
1.82
Enterprise Value/EBITDA
10.18
Financial Highlights
Profitability and Income Statement
Profit Margin
9.50%
Return on Assets (ttm)
7.18%
Return on Equity (ttm)
17.09%
Revenue (ttm)
820.76M
Net Income Avi to Common (ttm)
77.94M
Diluted EPS (ttm)
1.10
Balance Sheet and Cash Flow
Total Cash (mrq)
98.26M
Total Debt/Equity (mrq)
78.26%
Levered Free Cash Flow (ttm)
49.45M